Arcadia Biosciences grants director 10K options

A director of Arcadia Biosciences received a 10,000-share stock option grant with a $0.46 exercise price vesting by the next annual meeting.

Rhea-AI Filing Summary

Arcadia Biosciences, Inc. (RKDA) reported that director Amy Yoder received a grant of stock options covering 10,000 shares of common stock on September 10, 2026. The options have an exercise price of $0.46 per share and expire on September 10, 2036. They vest 100% on the earlier of September 10, 2027 or the next Annual Meeting of Stockholders, subject to her continued service, after which her directly held derivative position reported in this grant totals 23,442 options.

Insider Trade Summary

Grant/Award: 10,000 shares

Grant/Award 1 txn

Insider Yoder Amy

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	10,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 23,442 contracts (Direct)

Footnotes (1)

1. F1. The Option will become 100% vested and exercisable on the earlier to occur of (i) September 10, 2027 or (ii) the date of the Issuer's next Annual Meeting of Stockholders, subject to the Participant's continued service.

Key Figures

Options granted: 10,000 options Exercise price: $0.46 per share Expiration date: September 10, 2036 +2 more

5 metrics

Options granted 10,000 options Stock option grant to director on September 10, 2026

Exercise price $0.46 per share Exercise price of newly granted stock options

Expiration date September 10, 2036 Option term for the new grant

Post-grant derivative holdings 23,442 options Total directly held derivative securities after the transaction

Vesting date reference September 10, 2027 Latest date by which options vest if no earlier annual meeting occurs

Key Terms

Stock Option (Right to Buy), exercise price, vesting, Annual Meeting of Stockholders

4 terms

Stock Option (Right to Buy) financial

"security titled "Stock Option (Right to Buy)" was granted"

exercise price financial

"conversion or exercise price of $0.4600 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The Option will become 100% vested and exercisable"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Annual Meeting of Stockholders regulatory

"earlier to occur of September 10, 2027 or the date of the Issuer's next Annual Meeting of Stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did RKDA disclose for director Amy Yoder?

Arcadia Biosciences disclosed that director Amy Yoder received a grant of stock options for 10,000 shares on September 10, 2026, with an exercise price of $0.46 per share, expiring on September 10, 2036, subject to vesting conditions.

What are the vesting terms of the new stock options reported by RKDA?

The option grant to Amy Yoder will become 100% vested and exercisable on the earlier of September 10, 2027 or the date of Arcadia Biosciences' next Annual Meeting of Stockholders, subject to her continued service.

What is the exercise price of the new RKDA stock options granted to the director?

The stock options granted to director Amy Yoder have an exercise price of $0.46 per share for the underlying common stock of Arcadia Biosciences.

When do the newly granted RKDA stock options expire?

The stock options granted to Amy Yoder expire on September 10, 2036, giving a 10-year term from the grant date for potential exercise once vested.

How many derivative securities does the RKDA director hold after this option grant?

Following this option grant, Amy Yoder is reported as directly holding 23,442 stock options linked to Arcadia Biosciences common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 04:04 PM Accepted by SEC EDGAR 09/14/2026 - 04:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yoder Amy

(Last) (First) (Middle)

C/O ARCADIA BIOSCIENCES, INC.

5956 SHERRY LANE, SUITE 2000

(Street)

DALLAS TEXAS 75225

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arcadia Biosciences, Inc. [ RKDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.46	09/10/2026		A		10,000		(1)	09/10/2036	Common Stock	10,000	$0	23,442	D

Explanation of Responses:

1. The Option will become 100% vested and exercisable on the earlier to occur of (i) September 10, 2027 or (ii) the date of the Issuer's next Annual Meeting of Stockholders, subject to the Participant's continued service.

	Amy Yoder, by Attorney-in-fact, Solaeta Chan	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)